IP Library › Granted Patent US 12,479,898
Granted Patent B2
US 12,479,898 · App. 18/327,423 · Granted Nov 25, 2025

Pharmaceutical composition comprising immunoglobulin fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases

Inventors: Moon Cheol Kang (Pohang-si, KR); Young Woo Choi (Pohang-si, KR); Donghoon Choi (Yongin-si, KR); Young Chul Sung (Seoul, KR)
Assignee: GENEXINE, INC.
C07K14/5418A61K9/0034A61K9/08A61K38/2046A61K47/02A61P35/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,479,898
App. No.
18/327,423
Granted
Nov 25, 2025
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.

Claims (24)

1 . A pharmaceutical composition comprising an interleukin-7 (IL-7) fusion protein, wherein the IL-7 fusion protein comprises an IL-7 protein, an immunoglobulin Fc region, and an oligopeptide;

wherein the IL-7 protein comprises: (a) amino acid residues 26-177 of the amino acid sequence set forth in SEQ ID NO: 1; (b) amino acid residues 26-154 of the amino acid sequence set forth in SEQ ID NO: 2; (c) amino acid residues 26-154 of the amino acid sequence set forth in SEQ ID NO: 3; (d) amino acid residues 26-177 of the amino acid sequence set forth in SEQ ID NO: 4; (e) amino acid residues 26-176 of the amino acid sequence set forth in SEQ ID NO: 5; or (f) amino acid residues 26-178 of the amino acid sequence set forth in SEQ ID NO: 6;

wherein the immunoglobulin Fc region comprises the amino acid sequence set forth in any one of SEQ ID NOs: 9 to 14; and

wherein the oligopeptide is selected from the group consisting of methionine, glycine, methionine-methionine, glycine-glycine, methionine-glycine, glycine-methionine, methionine-methionine-methionine, methionine-methionine-glycine, methionine-glycine-methionine, glycine-methionine-methionine, methionine-glycine-glycine, glycine-methionine-glycine, glycine-glycine-methionine, methionine-methionine-methionine, and glycine-glycine-glycine.

2 . The pharmaceutical composition of claim 1 , wherein the IL-7 protein is conjugated to the N-terminus or C-terminus of the immunoglobulin Fc region.

3 . The pharmaceutical composition of claim 1 , wherein the IL-7 protein comprises amino acid residues 26-177 of the amino acid sequence set forth in SEQ ID NO: 1.

4 . The pharmaceutical composition of claim 1 , wherein the IL-7 fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 21-27.

5 . A modified interleukin-7 (IL-7) fusion protein comprising an IL-7 protein, an immunoglobulin Fc region, and an oligopeptide;

wherein the IL-7 protein comprises: (a) amino acid residues 26-177 of the amino acid sequence set forth in SEQ ID NO: 1; (b) amino acid residues 26-154 of the amino acid sequence set forth in SEQ ID NO: 2; (c) amino acid residues 26-154 of the amino acid sequence set forth in SEQ ID NO: 3; (d) amino acid residues 26-177 of the amino acid sequence set forth in SEQ ID NO: 4; (e) amino acid residues 26-176 of the amino acid sequence set forth in SEQ ID NO: 5; or (f) amino acid residues 26-178 of the amino acid sequence set forth in SEQ ID NO: 6;

wherein the immunoglobulin Fc region comprises the amino acid sequence set forth in any one of SEQ ID NOs: 9 to 14; and

wherein the oligopeptide is selected from the group consisting of methionine, glycine, methionine-methionine, glycine-glycine, methionine-glycine, glycine-methionine, methionine-methionine-methionine, methionine-methionine-glycine, methionine-glycine-methionine, glycine-methionine-methionine, methionine-glycine-glycine, glycine-methionine-glycine, glycine-glycine-methionine, methionine-methionine-methionine, and glycine-glycine-glycine.

6 . The modified IL-7 fusion protein of claim 5 , wherein the IL-7 protein comprises amino acid residues 26-177 of the amino acid sequence set forth in SEQ ID NO: 1.

7 . The modified IL-7 fusion protein of claim 5 , which comprises the amino acid sequence set forth in any one of SEQ ID NOs: 21-27.

8 . The pharmaceutical composition of claim 2 , wherein the IL-7 protein is conjugated to the N-terminus of the immunoglobulin Fc region.

9 . The pharmaceutical composition of claim 2 , wherein the IL-7 protein consists of amino acid residues 26-177 of the amino acid sequence set forth in SEQ ID NO: 1.

10 . The pharmaceutical composition of claim 1 , wherein the IL-7 protein is conjugated to the C-terminus of the oligopeptide.

11 . The pharmaceutical composition of claim 1 , wherein the oligopeptide is methionine-glycine-methionine.

12 . The pharmaceutical composition of claim 4 , wherein the IL-7 fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 24.

13 . The modified IL-7 fusion protein of claim 5 , wherein the IL-7 protein is conjugated to the N-terminus or C-terminus of the immunoglobulin Fc region.

14 . The modified IL-7 fusion protein of claim 13 , wherein the IL-7 protein is conjugated to the N-terminus of the immunoglobulin Fc region.

15 . The modified IL-7 fusion protein of claim 5 , wherein the IL-7 protein consists of amino acid residues 26-177 of the amino acid sequence set forth in SEQ ID NO: 1.

16 . The modified IL-7 fusion protein of claim 5 , wherein the IL-7 protein is conjugated to the C-terminus of the oligopeptide.

17 . The modified IL-7 fusion protein of claim 5 , wherein the oligopeptide is methionine-glycine-methionine.

18 . The modified IL-7 fusion protein of claim 5 , wherein the IL-7 fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 24.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2025
From: KANG, MOON CHEOL; CHOI, YOUNG WOO; CHOI, DONGHOON; SUNG, YOUNG CHUL
To: GENEXINE, INC.
Reel/Frame 070349/0801 →
Continuity (5)
Continuation 15775182
Provisional Application 62361170 · Jul 12, 2016
Provisional Application 62360696 · Jul 11, 2016
Provisional Application 62263262 · Dec 4, 2015
Related Publication 20240018205A1 · Jan 18, 2024
References Cited (96)
US 5093242A · Bachmair et al. · 1992 [cited by applicant]
US 6153380A · Nolan et al. · 2000 [cited by applicant]
US 7585947B2 · Morre et al. · 2009 [cited by applicant]
US 7589179B2 · Gillies et al. · 2009 [cited by applicant]
US 7867491B2 · Yang et al. · 2011 [cited by applicant]
US 8153114B2 · Morre et al. · 2012 [cited by applicant]
US 8338575B2 · Lauder et al. · 2012 [cited by applicant]
US 10208099B2 · Yang et al. · 2019 [cited by applicant]
US 10818928B2 · Tanaka · 2020 [cited by applicant]
US 10844104B2 · Yang et al. · 2020 [cited by applicant]
US 20020127564A1 · Nolan et al. · 2002 [cited by applicant]
US 20050054054A1 · Foss · 2005 [cited by examiner]
US 20050164352A1 · Lauder · 2005 [cited by examiner]
US 20050249701A1 · Morre et al. · 2005 [cited by applicant]
US 20060141581A1 · Gillies · 2006 [cited by examiner]
US 20080206190A1 · Morre et al. · 2008 [cited by applicant]
US 20080300188A1 · Yang · 2008 [cited by examiner]
US 20100196312A1 · Morre et al. · 2010 [cited by applicant]
US 20110243887A1 · Lauder et al. · 2011 [cited by applicant]
US 20120017104A1 · Morre et al. · 2012 [cited by applicant]
US 20130217864A1 · Cho et al. · 2013 [cited by applicant]
US 20140178393A1 · Andres et al. · 2014 [cited by applicant]
US 20140377218A1 · Morre et al. · 2014 [cited by applicant]
EP 0314415B1 · 1994 [cited by applicant]
EP 0877752B1 · 2003 [cited by applicant]
JP H02501618A · 1990 [cited by applicant]
JP 2000504220A · 2000 [cited by applicant]
JP 2001509661A · 2001 [cited by applicant]
JP 2009501543A · 2009 [cited by applicant]
JP 2010531134A · 2010 [cited by applicant]
JP 2014147396A · 2014 [cited by applicant]
JP 201557392A · 2015 [cited by applicant]
KR 20060112673A · 2006 [cited by applicant]
KR 20090045953A · 2009 [cited by applicant]
KR 20120041139A · 2012 [cited by applicant]
KR 20140004802A · 2014 [cited by applicant]
KR 20170066265A · 2017 [cited by applicant]
WO WO1997027213A1 · 1997 [cited by applicant]
WO WO2004018681A2 · 2004 [cited by applicant]
WO WO2005021592A2 · 2005 [cited by applicant]
WO WO2007019232A2 · 2007 [cited by applicant]
WO WO2009101737A1 · 2009 [cited by applicant]
WO WO2015015516A2 · 2015 [cited by applicant]
Bowie et al. Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions. Science, 1990, 247:1306-1310 (Year: 1990). [cited by examiner]
Burgess et al. Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single L… [cited by examiner]
Lazar et al. Transforming Growth Factoralpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities. Mol. Cell. Biol., 8:1247-1252, 1988 (Year: 1988). [cited by examiner]
Bork. Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Research, 2000; 10:398-400 (Year: 2000). [cited by examiner]
Greenspan et al. 1999. Defining epitopes: It's not as easy as it seems; Nature Biotechnology, 17:936-937 (Year: 1999). [cited by examiner]
Seo et al. Crucial roles of IL-7 in the development of T follicular helper cells and in the induction of humoral immunity. Journal of Virology, 2014; 88(16): 8998-9009 (Year: 2014). [cited by examiner]
Nam, H.J., et al., “Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fe as a genetic adjuvant,” European Journal of Immunology 40:351-358, Wiley-VCH, United States (Feb. 201… [cited by applicant]
Seo, N., et al., “Crucial Roles of Interleukin-7 in the Development of T Follicular Helper Cells and in the Induction of Humoral Immunity,” Journal of Virology, 88:8998-9009, American Society for Microbiology, United St… [cited by applicant]
International Search Report for International Application No. PCT/KR2016/014127, Korean Intellectual Property Office, Republic of Korea, mailed on Mar. 9, 2017, 8 pages. [cited by applicant]
Kroncke, R., et al., “Human follicular dendritic cells and vascular cells produce interleukin-7: a potential role for interleukin-7 in the germinal center reaction,” Eur. J. Immunol 26:2541-2544, Wiley-VCH, United State… [cited by applicant]
Pellegrini, M., et al., “IL-7 Engages Multiple Mechanisms to Overcome Chronic Viral Infection and Limit Organ Pathology,” Cell 144:601-613, Elsevier, Netherlands (Feb. 2011). [cited by applicant]
Miyakama, T., et al., “Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor”, Proc. Natl. Acad. Sci. USA, 90:10056-10060, National Academy of Sciences, United States (Nov. 1993). [cited by applicant]
Kang, M.C., et al., “Intranasal Introduction of Fe-Fused Interleukin-7 Provides Long-Lasting Prophylaxis against Lethal Influenza Virus Infection,” Journal of Virology, 90(5):2273-2284, American Society for Microbiology… [cited by applicant]
Muegge, K., et al., “Interleukin-7: A Cofactor for V(D)J Rearrangement of the T Cell Receptor B Gene,” Science 261:93-95, American Association for the Advancement of Science, United States (Jul. 1993). [cited by applicant]
Nanjappa, S.G., et al., “Immunotherapeutic effects of IL-7 during a chronic viral infection in mice,” Blood 117(19):5123-5132, American Society of Hematology, United States (May 2011). [cited by applicant]
NCBI, PDB: 4C54_A (Feb. 5, 2014), “Chain A, Crystal Structure of Recombinant Human lgg4 Fe”, 2 pages. [cited by applicant]
Patel, A., et al., “Treatment of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia,” J Antimicrob Chemotherapy 65:2489-2492, Oxford University Press, United Kingdom (Dec. 2010). [cited by applicant]
Pellegrini, M., et al., “Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies,” Nature Medicine 15(5):528-536, Springer, Germany (May 2009). [cited by applicant]
Rosenberg, S.A., et al., “IL-7 Administration to Humans Leads to Expansion of CDS+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells,” J Immunother 29(3):313-319, BMJ Publishing Group Ltd, United Kingdom… [cited by applicant]
Sawa, Y., et al., “Hepatic Interleukin-7 Expression Regulates T Cell Responses,” Immunity 30:447-457, Cell Press, United States (Mar. 2009). [cited by applicant]
Snyder, K.M., et al., “IL-7 in allogeneic transplant: Clinical promise and potential pitfalls,” Leukemia & Lymphoma, 47(7): 1222-1228, Informa, United Kingdom (Jul. 2006). [cited by applicant]
Voet, D., et al., Biochemistry, pp. 126-128 and 228-234, John Wiley & Sons Inc., United States (1990). [cited by applicant]
Watanabe, M., et al., “Interleukin 7 Is Produced by Human Intestinal Epithelial Cells and Regulates the Proliferation of Intestinal Mucosal Lymphocytes,” J. Clin. Invest. 95:2945-2953, American Society for Clinical Inve… [cited by applicant]
Office Action for European Patent Application No. 16807859.0, dated May 15, 2019, European Patent Office, Munich, Germany, 15 pages. [cited by applicant]
Office Action for European Patent Application No. 16807859.0, dated Dec. 19, 2018, European Patent Office, Munich, Germany, 16 pages. [cited by applicant]
Fry, T.J., et al., “Interleukin-7: from bench to clinic,” Blood 99(11):3892-3904, American Society of Hematology, United States (Jun. 2001). [cited by applicant]
Genbank, “interleukin-7 [synthetic construct]”, Accession No. AAB70834.1 (Sep. 21, 1997), accessed at https://ncbi.nlm.nih.gov/protein/2425099?report=genbank& log$=protalign&blast_rank=1&RID+IDFIPM40014, accessed on Nov… [cited by applicant]
Heufler, C., et al., “Interleukin 7 Is Produced by Murine and Human Keratinocytes,” J. Exp. Med. 178:1109-1114, The Rockefeller University Press, United States (Sep. 1993). [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/KR2016/006214, The International Bureau of WIPO, mailed on Dec. 12, 2017, 11 pages. [cited by applicant]
International Search Report for International Application No. PCT/KR2016/006214, Korean Intellectual Property Office, Republic of Korea, mailed on Aug. 24, 2016, 6 pages. [cited by applicant]
International Search Report for International Application No. PCT/KR2016/013966, Korean Intellectual Property Office, Republic of Korea, mailed on Mar. 2, 2017, 6 pages. [cited by applicant]
International Search Report for International Application No. PCT/KR2016/012495, Korean Intellectual Property Office, Republic of Korea, mailed on Jan. 13, 2017, 4 pages. [cited by applicant]
Office action for Japanese Patent Application No. 2017-564121 dated Jan. 8, 2019, 8 pages. [cited by applicant]
Bork, P., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research 10:398-400, Cold Spring Harbor Laboratory Press, United States (Apr. 2000). [cited by applicant]
Greenspan, N.S., et al., “Defining epitopes: It's not as easy as it seems,” Nature Biotechnology, 17:936-937, Springer, Germany (1999). [cited by applicant]
Fazeli, et al., “Efficacy of HPV-16 E7 Based Vaccine in a TC-1 Tumoric Animal Model of Cervical Cancer,” Cell Journal 12:483-488 (2010). [cited by applicant]
Choi, Y., et al., “Intravaginal Fc-fused IL-7 attract DNA vaccine-induced CD8 T cell in the genital tract,” Cytokine 76(1):80, Elsevier, Netherlands (Sep. 2015). [cited by applicant]
Sin, J., et al., “Interleukin 7 Can Enhance Antigen-Specific Cytotoxic-T-Lymphocyte and/or Th2-Type Immune Responses In Vivo,” Clinical and Diagnostic Laboratory Immunology 7(5):751-758, American Society for Microbiolog… [cited by applicant]
Huston, W., et al., “Vaccination to protect against infection of the female reproductive tract,” Expert Rev. Clin. Immunol. 8(1):81-94, Informa, United Kingdom (Jan. 2012). [cited by applicant]
Gottlieb, S., et al., “Future prospects for new vaccines against sexually transmitted infections,” Curr Opin Infect Dis. 30(1):77-86, Lippincott Williams & Wilkins, United States (Feb. 2017). [cited by applicant]
Bowie, J.U., et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science 247:1306-1310, American Association for the Advancement of Science, United States (Mar. 1990). [cited by applicant]
Whisstock, J.C., et al., “Prediction of protein function from protein sequence and structure,” Quarterly Reviews in Biophysics. 36(3):307-340, Cambridge University Press , United Kingdom (Aug. 2003). [cited by applicant]
Burgess, W.H., et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a… [cited by applicant]
Lazar, E., et al., “Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Mol. Cell. Biol. 8:1247-1252, American Society for Microbiology, United Stat… [cited by applicant]
Soong, R-S., et al., “Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ,” Clin. Cancer Res. 20:5456-67, American Associ… [cited by applicant]
Abraham, E., et al., “Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response,” J Immunol 149(11):3719-26 (Dec. 1992). [cited by applicant]
Genbank, “Interleukin-7 (precursor)”, Accession No. P13232 (Jan. 1, 1990), accessed at https://www.ncbi.nim.nih.gov/protein/P13232/, accessed on Sep. 27, 2023, 5 pages. [cited by applicant]
Genbank, “Interleukin-7 (precursor)”, Accession No. P56478 (Jul. 15, 1998), accessed at https://www.ncbi.nlm.nih.gov/protein/P56478/, accessed on Sep. 27, 2023, 2 pages. [cited by applicant]
Genbank, “Interleukin-7 (precursor)”, Accession No. P10168 (Jul. 1, 1989), accessed at https://www.ncbi.nlm.nih.gov/protein/P10168/, accessed on Sep. 27, 2023, 2 pages. [cited by applicant]
Genbank, “interleukin-7 precursor [Chlorocebus sabaeus]”, Accession No. NP 001279008 (May 21, 2014), accessed at https://www.ncbi.nlm.nih.gov/protein/NP_001279008.1/, accessed on Sep. 27, 2023, 1 page. [cited by applicant]
Genbank, “Interleukin-7 (precursor)”, Accession No. P26895 (Aug. 1, 1992), accessed at https://www.ncbi.nlm.nih.gov/protein/P26895/, accessed on Sep. 27, 2023, 2 pages. [cited by applicant]
Genbank, “Interleukin-7 (precursor)”, Accession No. Q28540 (Nov. 1, 1997), accessed at https://www.ncbi.nlm.nih.gov/protein/Q28540/, accessed on Sep. 27, 2023, 2 pages. [cited by applicant]
Kim, E-S., et al., “Controlled Release of Human Growth Hormone Fused With a Human Hybrid Fc Fragment through a nanoporous polymer membrane,” Nanoscale 5(10):4262-4269, RSC Pub, United Kingdom (May 2013). [cited by applicant]